References
[1] Liu Zongchao, Li Zhexuan, Zhang Yang, et al. Interpretation on the report of Global Cancer Statistics 2020 [J]. Journal of Multidisciplinary Cancer, 2021, 7(02):1-14.
[2] Lerner SP, Robertson AG. Molecular Subtypes of Non-muscle Invasive Bladder Cancer [J]. Cancer Cell, 2016, 30(1): 1-3.
[3] Wang Z, Gao W, Li J, et al. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population [J]. J Cancer, 2020, 11(7): 1668-78.
[4] Colombo R, Moschini M. Role of the combined regimen with local chemotherapy and Mw-induced hyperthermia for non-muscle invasive bladder cancer management. A systematic review [J]. Urologia, 2013, 80(2): 112-9.
[5] Dingjiu Li, province Huzi, Yubin Zhong. Tumour thermotherapy [M]. Zhengzhou: Zhengzhou University Press, 2003.
[6] Juang T, Stauffer PR, Craciunescu OA, et al. Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer [J]. Int J Hyperthermia, 2014, 30(3): 176-83.
[7] Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review [J]. Eur Urol, 2011, 60(1): 81-93.
[8] Rath-Wolfson L, Moskovitz B, Dekel Y, et al. Combined intravesical hyperthermia and mitomycin chemotherapy: a preliminary in vivo study [J]. Int J Exp Pathol, 2003, 84(3): 145-52.
[9] Sousa A, Pineiro I, Rodriguez S, et al. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer [J]. Int J Hyperthermia, 2016, 32(4): 374-80.
[10] Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma [J]. J Clin Oncol, 2003, 21(23): 4270-6.
[11] Cui Shuzhong, Wang Jiahong, Zhang Xiangliang. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal metastasis from colorectal cancer [J]. Chinese Journal of Clinical Oncology, 2012, 39(22):1691-1695.
[12] Liu Meide, Zhang Yingjie. Curative Effect Comparative Analysis of Hyperthermic Perfusion Therapy and Mitomycin Perfusion Chemotherapy after Transurethral Resection of Bladder Tumour [J]. Chinese and Foreign Medical Research, 2015, 13(07):17-18.
[13] Gao Fei, WangGuirong. Intravesical Mitomycin Hyperthemal Perfusion Combined with Transurethral Resection for Treating Bladder Cancer in 32 Cases [J]. China Pharmaceuticals, 2015, 24(17):85-86.
[14] Wang Yu, LiYugang, Hong Jian, et al. The primary clinical application of hyperthermic intravesical chemotherapy in the prevention of non-muscle-invasive bladder cancer recurrence after transurethral resection of bladder tumour [J]. Journal of Modern Urology, 2017, 22(12):903-906.
[15] Liu Qingyuan, Duan Xiaoyu, Wang Lingdian, et al. Effect of hvperthermic intravesical chemotherapy versus normothermiaintravesical chemotherapy on non-muscle invasive bladder cancer [J]. Journal of Chinese Practical Diagnosis and Therapy, 2017, 31(02):174-175.
[16] Ruan Q, Ding D, Wang B, et al. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer [J]. Cancer Biol Med, 2021, 18(1): 308-17.
[17] Geijsen ED, de Reijke TM, Koning CC, et al. Combining Mitomycin C and Regional 70 MHz Hyperthermia in Patients with Nonmuscle Invasive Bladder Cancer: A Pilot Study [J]. J Urol, 2015, 194(5): 1202-8.
[18] Grimberg DC, Dudinec J, Shah A, et al. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage [J]. Urol Oncol, 2021, 39(8): 498 e13- e20.
[19] van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue [J]. Int J Hyperthermia, 2018, 34(7): 988-93.
[20] Doisy L, Cimier A, Adypagavane A, et al. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy [J]. Int J Hyperthermia, 2021, 38(1): 1633-8.